Pfizer Inc. announced yesterday that it is discontinuing global clinical development of bococizumab, a monoclonal antibody inhibitor of PCSK9 that was being investigated as a lipid-lowering drug. After completing the last of six planned clinical efficacy studies of bococizumab, Pfizer stated that it observed that the drug’s lipid-lowering activity declines…